Mathematical modeling of viral kinetics: a tool to understand and optimize therapy.

[1]  Rachel S. Levy-Drummer,et al.  First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline , 2002, Journal of viral hepatitis.

[2]  Rachel S. Levy-Drummer,et al.  Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C , 2002, Journal of viral hepatitis.

[3]  L. Weinberger,et al.  Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. , 2002, Journal of hepatology.

[4]  M. Buti,et al.  Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirin , 2002, Hepatology.

[5]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[6]  A. Neumann,et al.  Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: a case control study , 2001, BMC gastroenterology.

[7]  Alan S. Perelson,et al.  Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed , 2001, Hepatology.

[8]  P. Ferenci,et al.  Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study , 2001, The Lancet.

[9]  A. Neumann,et al.  Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. , 2001, Gastroenterology.

[10]  S. Hadziyannis,et al.  Induction interferon therapy in naïve patients with chronic hepatitis C: increased end‐of‐treatment virological responses but absence of long‐term benefit , 2001, Alimentary pharmacology & therapeutics.

[11]  B. Hansen,et al.  Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. , 2001, Journal of hepatology.

[12]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[13]  J. Albrecht,et al.  The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. , 2000, Gastroenterology.

[14]  H. Conjeevaram,et al.  A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype , 2000, American Journal of Gastroenterology.

[15]  A S Perelson,et al.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. , 2000, The Journal of infectious diseases.

[16]  F. Nevens,et al.  Daily induction combination treatment with alfa2b interferon or standard combination treatment in naive chronic hepatitis C patients. A controlled multicenter randomized trail. , 2000 .

[17]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.

[18]  William M. Lee,et al.  Racial differences in responses to therapy with interferon in chronic hepatitis C , 1999, Hepatology.

[19]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[20]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[21]  H. Niesters,et al.  Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. , 1999, Journal of hepatology.

[22]  William M. Lee,et al.  Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C , 1998, Hepatology.

[23]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[24]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[25]  H. Van Vlierberghe,et al.  Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. , 1998, Journal of hepatology.

[26]  S. Zeuzem,et al.  Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfa , 1998, Hepatology.

[27]  J. Prieto,et al.  Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. , 1997, Gastroenterology.

[28]  J. Schmidt,et al.  Dynamics of hepatitis B virus infection in vivo. , 1997, Journal of hepatology.

[29]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[30]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[31]  C. Rice,et al.  The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. , 1997, Journal of immunology.

[32]  T. Ohmura,et al.  Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. , 1997, The American journal of gastroenterology.

[33]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[35]  J. Schmidt,et al.  Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo , 1996, Hepatology.

[36]  M. Mizokami,et al.  Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C , 1995, Journal of medical virology.

[37]  H. Thomas,et al.  Which patients with chronic hepatitis B virus infection will respond to α‐interferon therapy? A statistical analysis of predictive factors , 1989, Hepatology.